Alzheimer’s Disease – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms – Claims Data Analysis (US)

According to Clarivate Epidemiology, there are approximately 4 million prevalent cases of Alzheimer’s disease (AD) and nearly 2.5 million prevalent cases of mild cognitive impairment (MCI) due to AD in the United States in 2022. Approved options are limited to only modestly effective procognitive symptomatic agents (e.g., donepezil, memantine) and Aduhelm (aducanumab), the first potential DMT for this debilitating disease whose launch has been met with considerable headwinds. Other anti-beta amyloid DMTs (Eisai / Biogen’s lecanemab, Eli Lilly’s donanemab, Roche’s gantenerumab) and several therapies for treating AD-associated psychosis (Acadia’s Nuplazid) and agitation (Lundbeck / Otsuka’s Rexulti, Avanir / Otsuka’s AVP-786, Axsome’s AXS-05, BioXcel’s BXCL-501) are advancing through late-phase development with near-term launch potential. As the AD therapy market enters a new era of treatment choice, understanding today’s treatment landscape and the patient journey is important for emerging players bringing novel brands to this large, underserved, and mostly generic market. Our Treatment Algorithms: Claims Data Analysis content provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AD patients?
• What is the dynamic between memantine IR / XR formulations now that both are generic? How has Namzaric been integrated into the treatment algorithm, and what is its source of business?
• What percentage of AD patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
• What percentage of AD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Eisai, Novartis, AbbVie, AstraZeneca, Eli Lilly, Johnson & Johnson, Lundbeck / Otsuka, Acadia Pharmaceuticals.

Key drugs: Donepezil, galantamine, rivastigmine, rivastigmine patch, memantine IR, memantine XR, Namenda XR, Namzaric, antipsychotics, antidepressants.

SOLUTION ENHANCEMENT

The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.